Anzeige
Mehr »
Mittwoch, 13.05.2026 - Börsentäglich über 12.000 News
Bahnbrechende KI-Lösung "Ohne Nadelstiche" als Ersatz für herkömmliche Bluttests "unlocked"?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1XDTV | ISIN: NL0010696654 | Ticker-Symbol: UQ1
Tradegate
13.05.26 | 20:09
24,200 Euro
-2,42 % -0,600
1-Jahres-Chart
UNIQURE NV Chart 1 Jahr
5-Tage-Chart
UNIQURE NV 5-Tage-Chart
RealtimeGeldBriefZeit
24,20024,35020:35
24,25024,35020:35

Aktuelle News zur UNIQURE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoFDA to reconsider shock rejection of cell therapy Ebvallo. Could uniQure be next?12
05.05.UniQure plans U.K. AMT-130 MAA submission in Q3 as it expects cash runway into H2 20295
05.05.Transcript: uniQure Q1 2026 Earnings Conference Call13
05.05.uniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates3
UNIQURE Aktie jetzt für 0€ handeln
05.05.UniQure N.V. Q1 Loss Widens1
05.05.uniQure Inc.: uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates413~ Advancing FDA interactions on AMT-130 for Huntington's disease; Type B meeting scheduled for the second quarter of 2026 ~ ~ Progressing AMT-130 toward expected UK regulatory submission; MAA on...
► Artikel lesen
05.05.uniQure N.V. - 10-Q, Quarterly Report4
04.05.uniQure Q1 2026 Earnings Preview6
30.04.UniQure, in 'symbolic' win, to seek UK approval of Huntington's gene therapy10
30.04.uniQure rises after regulatory updates on gene therapy2
30.04.uniQure plans UK filing for Huntington's gene therapy AMT-1308
30.04.uniQure Inc.: uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington's Disease362~ Submission of a UK Marketing Authorization Application for AMT-130 is expected in the third quarter of 2026 ~ ~ Type B Meeting with U.S. FDA granted in second quarter; expect to discuss potential...
► Artikel lesen
30.04.uniQure N.V. - 8-K, Current Report2
28.04.uniQure Inc.: uniQure to Announce First Quarter 2026 Financial Results343 ~ uniQure to host earnings call on Tuesday, May 5, 2026 at 8:30 a.m. ET ~ LEXINGTON, Mass. and AMSTERDAM, April 28, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company...
► Artikel lesen
22.04.uniQure N.V. (QURE) Stock Posts 30% Growth from Last Year3
13.04.Bronstein, Gewirtz & Grossman, LLC: Bronstein, Gewirtz & Grossman LLC Urges uniQure N.V. Investors to Act: Class Action Filed Alleging Investor Harm528New York, New York--(Newsfile Corp. - April 13, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed...
► Artikel lesen
12.03.uniQure upgraded at Mizuho on improved outlook for Huntington's asset AMT-13020
11.03.Uniqure To Rally Around 92%? Here Are 10 Top Analyst Forecasts For Wednesday6
10.03.Mizuho upgrades uniQure stock rating on FDA leadership change3
10.03.Führungswechsel bei der FDA: Mizuho stuft uniQure-Aktie auf "Outperform" hoch2
Weiter >>
113 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,3